Abstract: The present invention provides a compound of formula (I): ##STR1## wherein Y is oxygen; R.sup.2 and R.sup.3 are the same or different and are hydrogen or C.sub.1-4 alkyl; R.sup.4 is NR.sup.11 R.sup.12 ; R.sup.11, R.sup.12, R.sup.5 and R.sup.6 are the same or different and are hydrogen, C.sub.1-4 alkyl or C.sub.1-12 acyl; R.sup.7, R.sup.8, R.sup.9 and R.sup.10 are the same or different and are hydrogen, halo, C.sub.1-4 haloalkyl, C.sub.1-4 alkyl and C.sub.1-4 alkoxy; and n is 2, 3, 4 or 5; m is 0 or an integer from 1 to 5; or a salt thereof, methods for the preparation of the compounds of the formula (I), intermediates in their preparations, pharmaceutical formulations containing them, and their use in the treatment of neoplastic growth.

Abstract: A compound of the formula (I):ArCH.sub.2 R.sup.1where Ar is ##STR1## where Z is NH, NCH.sub.3 or NEt and R.sup.1 is an hydroxyalkylamino group and pharmaceutically acceptable salts thereof. The compounds are useful as antitumor agents.

Abstract: A lyophilised pharmaceutical formulation of tissue plasminogen activator and a process for its preparation by vacuum drying a frozen aqueous solution of thereof, in which the pH is from 2 to 5.

Abstract: Compounds of the formula (III): ##STR1## or salts or acyl derivatives thereof, for use as antifungal and antiprotozoal agents are disclosed. Compositions containing the compounds are also disclosed as are method for the preparation of the compounds and intermediates in their preparation.

Abstract: The present invention relates to compounds of formula (I)ArCH.sub.2 R.sup.

Abstract: A topical pharmaceutical formulation for use in treating virus infections of the skin or mucosa and containing 9-(2-hydroxyethoxymethyl) guanine or a salt or ester thereof which comprises a dispersed oil phase and a continuous aqueous phase containing therein water, at least 30% of a polyhydric alcohol (by weight of the formulation) and solublized acyclovir.

Abstract: Agglutination assays, particularly latex agglutination assays, for simultaneous testing for a multiplicity of ligands. The reagents for use in the assays comprise two or more insoluble colored substances, each substance being adapted to form a distinctively colored agglutinate in the presence of a specific ligand or specific group of ligands.

Abstract: Agglutination assays, particularly latex agglutination assays, for simultaneous testing for a multiplicity of ligands. The reagents for use in the assays comprise two or more insoluble colored substances, each substance being adapted to form a distinctively colored agglutinate in the presence of a specific ligand or specific group of ligands.

Abstract: Agglutination assays, particularly latex agglutination assays, for simultaneous testing for a multiplicity of ligands. The reagents for use in the assays comprise two or more insoluble colored substances, each substance being adapted to form a distinctively colored agglutinate in the presence of a specific ligand or specific group of ligands.

Abstract: A novel class of 2,4-diamino-6-(2,5-dialkoxybenzyl)-5-methyl[2,3-d]-pyrimidines is described. These compounds are antibacterial agents, active against certain Streptococcus species. They are also active antiproliferative agents.

Abstract: The present invention relates to certain amino acid exters of the purine nucleoside acyclovir, pharmaceutically acceptable salts thereof and their use in the treatment of herpes virus infections. The invention also includes pharmaceutical formulations and processes for the preparation of such compounds.

Abstract: The invention relates to a controlled release pharmaceutical formulation for oral administration which comprises discrete units comprising acrivastine or a salt thereof coated with a mixture containing:(a) a copolymer or polymer containing repeating monomer units selected from alkyl esters of acrylic and methacrylic acids and(b) ethyl cellulose,and a process for preparing such formulations.

Abstract: The present invention related to anti tumor compounds of formula (I)ArCH.sub.2 R.sup.1 (I)or a monomethyl or monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 29 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a fused tetracyclic aromatic ring system comprised of 5-membered and 6-membered rings and contains at least one heteroatom and 3 aromatic rings and a total of no more than 18 ring atoms, or a substituted derivative thereof; the heteratom is preferably oxygen, sulfur or nitrogen; when it is nitrogen this is substituted by hydrogen, methyl or ethyl;R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1;R.sup.5 is hydrogen;R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-5 alkyl optionally substituted by hydroxy;R.sup.8 and R.sup.9 are the same or different and each is hydrogen or C.sub.

Abstract: Pyrethroid esters of the formula (I) ##STR1## potentiate the activity of each other against arthropod pests. Values of R.sup.2 and R.sup.3 include halogen and R includes phenoxybenzyl and .alpha.-cyanophenoxybenzyl. Compositions comprise of two or more esters of (I) and formulations comprise such compositions in association with a carrier. The esters (I) are used to combat arthropods.

Abstract: The present invention provides a compound of formula (I): ##STR1## wherein R.sup.1 is hydrogen, C.sub.1-4 alkyl, acetyl or formyl; R.sup.2 and R.sup.3 are the same or different and are hydrogen or C.sub.1-4 alkyl; R.sup.4 is NR.sup.11 R.sup.12 ; R.sup.11, R.sup.12, R.sup.5 and R.sup.6 are the same or different and are hydrogen, C.sub.1-4 alkyl or C.sub.1-12 acyl; R.sup.7, R.sup.8, R.sup.9 and R.sup.10 are the same or different and are hydrogen, halo, C.sub.1-4 haloalkyl, C.sub.1-4 alkyl and C.sub.1-4 alkoxy; and n is 2, 3, 4 or 5; m is 0 or an integer from 1 to 6; or a salt thereof, methods for the preparation of the compounds of the formula (I), intermediates in their preparations, pharmaceutical formulations containing them, and their use in the treatment of tumors.

Abstract: The present invention is concerned with the compound of formula (I) ##STR1## and its acid addition salts. The invention is also directed to the use of the compound of formula (I) and its pharmaceutically acceptable acid addition salts as positive conotropic agents in mammals.

Abstract: The specification describes and claims methods of controlling acarine pests by application of a compound of Formula (I), methods of controlling arthropod pests by application of a compound of Formula (IA), compounds of Formula (IA) per se, pesticidal compositions comprising a compound of Formula (IA), and processes for preparing a compound of Formula (IA).

Abstract: A lyophilized pharmaceutical formulation of tissue plasminogen activator and a process for its preparation by vaccum drying a frozen aqueous solution of thereof, in which the pH is from 2 to 5.

Abstract: The present invention relates to compounds of formula I ##STR1## or a salt, ester or amide thereof; wherein R.sup.1 is --CH.sub.2 --CH.sub.2 --, CH.sub.2 --O-- or --O--CH.sub.2 --; R.sup.2 and R.sup.3 are the same or different and are each hydrogen, C.sub.1-4 alkyl or taken together with the nitrogen comprise a nitrogen-containing heterocyclic ring having four to six ring members; R.sup.4 is a single bond or a C.sub.1-7 bivalent aliphatic hydrocarbon group and may be joined to the aromatic ring system at the 2,3,8 or 9 positions; n is 0 to 3, and their use as antihistamine and antiasthma agents.

Abstract: This invention relates to a new synthetic process for the manufacture of zidovudine from the starting material D-xylose involving:(i) Conversion of D-xylose to a 1-(.beta.-D-xylofuranosyl)thymine derivative:(ii) 2'-Deoxygenation of the thymaine derivative; and(iii) 3'-Azidation of the 2'-deoxy compound.